CTIS2023-506854-19-00招募中1 期
IMA401-101
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid TumorsPatients with Advanced Solid TumorsCTIS2023-506390-35-00Tesaro Inc.840
招募中
1 期
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic DermatitisAtopic DermatitisCTIS2022-502997-18-00Bristol-Myers Squibb Services Unlimited Company64
进行中（未招募）
1 期
A Randomised, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy ParticipantsInflammatory diseaseMedDRA version: 20.0Level: LLTClassification code: 10021426Term: Immune system disorder (NOS) Class: 10021428CTIS2023-503917-31-00Immunorx Pharma Inc.81
进行中（未招募）
1 期
A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma.Adenoid cystic carcinoma (ACC)MedDRA version: 21.0Level: PTClassification code: 10053231Term: Adenoid cystic carcinoma Class: 100000004864CTIS2023-508476-11-00Remix Therapeutics Inc.80
招募中
1 期
Trial to evaluate the administration of IDOR-1134-2831 vaccine in healthy participantsClostridioides difficile (C. difficile)MedDRA version: 20.0Level: PTClassification code: 10054236Term: Clostridium difficile infection Class: 100000004862CTIS2023-506407-26-00Idorsia Pharmaceuticals Ltd.125